234 related articles for article (PubMed ID: 35536452)
1. Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.
Kostiainen I; Karppinen N; Simonen P; Rosengård-Bärlund M; Lindén R; Tarkkanen M; Gordin D; Rapola J; Schalin-Jäntti C; Matikainen N
Endocrine; 2022 Jun; 77(1):177-187. PubMed ID: 35536452
[TBL] [Abstract][Full Text] [Related]
2. Carcinoid heart disease in patients with midgut neuroendocrine tumours.
Delhomme C; Walter T; Arangalage D; Suc G; Hentic O; Cachier A; Alkhoder S; François L; Lombard-Bohas C; Iung B; Ruszniewski P; de Mestier L
J Neuroendocrinol; 2023 Apr; 35(4):e13262. PubMed ID: 37005217
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A (CgA) as a biomarker in carcinoid heart disease and NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs) related carcinoid syndrome.
Konsek-Komorowska SJ; Pęczkowska M; Kolasińska-Ćwikła AD; Konka M; Chrapowicki E; Ćwikła JB
Med Clin (Barc); 2022 Jul; 159(2):85-89. PubMed ID: 34736622
[TBL] [Abstract][Full Text] [Related]
5. Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease.
Dobson R; Cuthbertson DJ; Jones J; Valle JW; Keevil B; Chadwick C; Poston GP; Burgess MI
Neuroendocrinology; 2014; 99(2):85-93. PubMed ID: 24603343
[TBL] [Abstract][Full Text] [Related]
6. Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival: A Systematic Literature Review.
Buchanan-Hughes A; Pashley A; Feuilly M; Marteau F; Pritchard DM; Singh S
Neuroendocrinology; 2021; 111(1-2):1-15. PubMed ID: 32097914
[TBL] [Abstract][Full Text] [Related]
7. What do we know about carcinoid heart disease in the present era?
Pęczkowska M; Konsek-Komorowska SJ; Kolasińska-Ćwikła AD; Konka M; Michałowska I; Ćwikła JB
Kardiol Pol; 2022; 80(10):990-1001. PubMed ID: 36136036
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, one-year-incidence and predictors of carcinoid heart disease.
Mattig I; Franke MR; Pschowski R; Brand A; Stangl K; Knebel F; Dreger H
Cardiovasc Ultrasound; 2023 Sep; 21(1):18. PubMed ID: 37752548
[TBL] [Abstract][Full Text] [Related]
9. Echocardiography in functional midgut neuroendocrine tumors: When and how often.
Castillo JG; Naib T; Zacks JS; Adams DH
Rev Endocr Metab Disord; 2017 Dec; 18(4):411-421. PubMed ID: 29080935
[TBL] [Abstract][Full Text] [Related]
10. The role of N-terminal pro-brain natriuretic peptide, chromogranin A, and 5-hydroxyindoleacetic acid in screening for carcinoid heart disease.
Johnson KKN; Stemann Lau T; Mark Dahl Baunwall S; Elisabeth Villadsen G; Guldbrand Rasmussen V; Grønbaek H; Oksjoki RK; Dam G
J Neuroendocrinol; 2023 Oct; 35(10):e13327. PubMed ID: 37574797
[TBL] [Abstract][Full Text] [Related]
11. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality.
Dobson R; Burgess MI; Valle JW; Pritchard DM; Vora J; Wong C; Chadwick C; Keevi B; Adaway J; Hofmann U; Poston GJ; Cuthbertson DJ
Br J Cancer; 2014 Oct; 111(9):1703-9. PubMed ID: 25211656
[TBL] [Abstract][Full Text] [Related]
12. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
Korse CM; Taal BG; de Groot CA; Bakker RH; Bonfrer JM
J Clin Oncol; 2009 Sep; 27(26):4293-9. PubMed ID: 19667278
[TBL] [Abstract][Full Text] [Related]
13. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
Halperin DM; Shen C; Dasari A; Xu Y; Chu Y; Zhou S; Shih YT; Yao JC
Lancet Oncol; 2017 Apr; 18(4):525-534. PubMed ID: 28238592
[TBL] [Abstract][Full Text] [Related]
14. Management of Diarrhea in Patients With Carcinoid Syndrome.
Naraev BG; Halland M; Halperin DM; Purvis AJ; OʼDorisio TM; Halfdanarson TR
Pancreas; 2019 Sep; 48(8):961-972. PubMed ID: 31425482
[TBL] [Abstract][Full Text] [Related]
15. Metastatic small bowel neuroendocrine tumour with bilateral carcinoid heart disease.
Jahagirdar V; Kamal A; Steeds R; Ayuk J
BMJ Case Rep; 2016 Feb; 2016():. PubMed ID: 26843220
[TBL] [Abstract][Full Text] [Related]
16. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.
Khan MS; Walter T; Buchanan-Hughes A; Worthington E; Keeber L; Feuilly M; Grande E
World J Gastroenterol; 2020 Aug; 26(30):4537-4556. PubMed ID: 32874063
[TBL] [Abstract][Full Text] [Related]
17. Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort.
Grundmann E; Curioni-Fontecedro A; Christ E; Siebenhüner AR
BMC Cancer; 2023 Apr; 23(1):338. PubMed ID: 37055717
[TBL] [Abstract][Full Text] [Related]
18. Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration.
Das S; Stockton SS; Hassan SA
Oncologist; 2023 Jul; 28(7):575-583. PubMed ID: 37209415
[TBL] [Abstract][Full Text] [Related]
19. High tumour burden, delayed diagnosis and history of cardiovascular disease may be associated with carcinoid heart disease.
Alves C; Mesquita M; Silva C; Soeiro M; Hajjar L; Riechelmann RP
Ecancermedicalscience; 2018; 12():879. PubMed ID: 30483359
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours.
Lewis AR; Wang X; Magdalani L; D'Arienzo P; Bashir C; Mansoor W; Hubner R; Valle JW; McNamara MG
World J Gastroenterol; 2018 Feb; 24(6):671-679. PubMed ID: 29456406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]